Teriflunomide Male Transmission Study

Inclusion Criteria

• •1. Males with relapsing forms of multiple sclerosis appropriately treated with teriflunomide 14 mg po daily;
• •2. Continuous treatment for three months with good compliance as assessed by the investigator
• •3. Age between 18 and 55
• •4. Penile-vaginal intercourse with a female partner at least twice a month with unimpeded ejaculation.
• •5. Compliance with safety assessments, e.g., regular bloodwork for complete blood count and liver function testing as recommended in the Package Insert
• •6. Able to give informed consent
• •Females
• •1. Regular sexual intercourse with a male partner who is actively taking teriflunomide
• •2. Age between 18 and 55
• •3. Able to give informed consent
• •4. Negative urine pregnancy test at the time of blood sampling
• •5. Reliable contraception that does not involve barrier methods